TABLE I.
N (%) | N (%) | ||||||
---|---|---|---|---|---|---|---|
|
|
||||||
Characteristics | Overall (N = 66) | EBRT (N = 45) | CCRT (N = 21) | P-Value | WD/MD Histology (N = 32) | PD histology (N = 34) | P-Value |
| |||||||
Median follow-up (months) | 24.5 | 30.0 | 21.9 | 0.067 | 35.3 | 23.0 | 0.335 |
Age | |||||||
<45 years | 5 (7.6%) | 4 (8.9%) | 1 (4.8%) | 3 (9.4%) | 2 (5.9%) | ||
≥45 years | 61 (92.4%) | 41 (91.1%) | 20 (95.2%) | 0.555 | 29 (90.6%) | 32 (94.1%) | 0.592 |
Gender | |||||||
Male | 34 (51.5%) | 24 (53.3%) | 10 (47.6%) | 18 (56.3%) | 16 (47.1%) | ||
Female | 32 (48.5%) | 21 (46.7%) | 11 (52.4%) | 0.665 | 14 (43.8%) | 18 (52.9%) | 0.455 |
Tumor stage | |||||||
T1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
T2 | 5 (7.6%) | 3 (6.7%) | 2 (9.5%) | 3 (9.4%) | 2 (5.9%) | ||
T3 | 4 (6.1%) | 4 (8.9%) | 0 (0%) | 1 (3.1%) | 3 (8.8%) | ||
T4 | 57 (86.4%) | 38 (84.4%) | 19 (90.5%) | 0.353 | 28 (87.5%) | 29 (85.3%) | 0.560 |
Regional node stage | |||||||
N0 | 11 (16.7%) | 8 (17.8%) | 3 (14.3%) | 5 (15.6%) | 6 (17.6%) | ||
N1 | 55 (83.0%) | 37 (82.2%) | 18 (85.7%) | 0.723 | 27 (84.4%) | 28 (82.4) | 0.826 |
Distant metastasis | |||||||
No | 34 (51.5%) | 21 (46.7%) | 13 (61.9%) | 15 (46.9%) | 19 (55.9%) | ||
Yes | 32 (48.5%) | 24 (53.3%) | 8 (38.1%) | 0.249 | 17 (53.1%) | 15 (44.1%) | 0.464 |
Histology | |||||||
WD/MD | 32 (48.5%) | 26 (57.8%) | 6 (28.6%) | — | — | ||
PD | 34 (51.5%) | 19 (42.2%) | 15 (71.4%) | 0.027 | — | — | |
Concurrent chemotherapy | |||||||
EBRT | 45 (68.2%) | — | — | 26 (81.3%) | 19 (55.9%) | ||
CCRT | 21 (32.3%) | — | — | 6 (18.8%) | 15 (44.1%) | 0.027 | |
Radiation technique | |||||||
EBRT | 15 (22.7%) | 12 (26.7%) | 3 (14.3%) | 0.264 | 7 (21.9%) | 8 (23.5%) | 0.873 |
IMRT | 51 (77.3%) | 33 (73.3%) | 25 (78.1%) | 26 (76.5%) |
EBRT, external beam radiation therapy; CCRT, concurrent chemoradiation therapy; WD/MD histology, well-differentiated/moderately differentiated histology; PD histology, poorly differentiated histology; IMRT, intensity-modulated radiation therapy.